{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T22:54:38Z","timestamp":1773615278752,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T00:00:00Z","timestamp":1440979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ygyno.2015.08.026","type":"journal-article","created":{"date-parts":[[2015,9,6]],"date-time":"2015-09-06T10:15:56Z","timestamp":1441534556000},"page":"394-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation"],"prefix":"10.1016","volume":"139","author":[{"given":"Zhenqiu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmik","family":"Agadjanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul-Joseph","family":"Aspuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Orsulic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.08.026_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","article-title":"A framework for a personalized surgical approach to ovarian cancer","volume":"12","author":"Nick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0010","first-page":"111","article-title":"Surgical debulking of ovarian cancer: what difference does it make?","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0015","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/sj.bjc.6605292","article-title":"Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial","volume":"101","author":"Ferrandina","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2008.10.010","article-title":"A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma","volume":"112","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2006.07.7800","article-title":"Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer","volume":"25","author":"Axtell","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2015.08.026_bb0035","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/IGC.0b013e3181cff38b","article-title":"Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review","volume":"20","author":"Ibeanu","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0040","first-page":"CD009786","article-title":"Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer","volume":"2","author":"Rutten","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2015.03.049","article-title":"Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care","volume":"137","author":"Gomez-Hidalgo","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bjc.2012.376","article-title":"Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review","volume":"107","author":"Borley","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0055","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-14-0445","article-title":"Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer","volume":"20","author":"Tucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju048","article-title":"Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples","volume":"106","author":"Riester","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0065","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","article-title":"A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer","volume":"68","author":"Bonome","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0070","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bat013","article-title":"curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome","author":"Ganzfried","year":"2013","journal-title":"Database"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/amiajnl-2011-000658","article-title":"Identifying disease genes and module biomarkers by differential interactions","volume":"19","author":"Liu","year":"2012","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0085","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/bioinformatics\/btu778","article-title":"Multilevel regularized regression for simultaneous taxa selection and network construction with metagenomic count data","volume":"31","author":"Liu","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1467-9868.2010.00740.x","article-title":"Stability selection","volume":"72","author":"Meinshausen","year":"2010","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0095","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-13-1256","article-title":"A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer","volume":"20","author":"Cheon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0105","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.celrep.2013.07.010","article-title":"Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer","volume":"4","author":"Zhang","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/bmm.14.16","article-title":"Ten-gene biomarker panel: a new hope for ovarian cancer?","volume":"8","author":"Cheon","year":"2014","journal-title":"Biomark. Med"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0125","doi-asserted-by":"crossref","first-page":"e94476","DOI":"10.1371\/journal.pone.0094476","article-title":"Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease","volume":"9","author":"Brodsky","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0130","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","article-title":"TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment","volume":"73","author":"Yeung","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0135","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1038\/cddis.2013.442","article-title":"An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)","volume":"4","author":"Huang","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0140","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/1078-0432.CCR-14-3111","article-title":"Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer","volume":"21","author":"Ryner","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI0215518","article-title":"Evidence that fibroblasts derive from epithelium during tissue fibrosis","volume":"110","author":"Iwano","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0002-9440(10)63834-5","article-title":"Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma","volume":"162","author":"Petersen","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng.3224","article-title":"Stromal contribution to the colorectal cancer transcriptome","volume":"47","author":"Isella","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0165","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","article-title":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","volume":"47","author":"Calon","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1593\/neo.101720","article-title":"Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer","volume":"13","author":"Schauer","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12672-010-0054-2","article-title":"Microenvironment and pathogenesis of epithelial ovarian cancer","volume":"1","author":"Saad","year":"2010","journal-title":"Horm. Cancer"},{"key":"10.1016\/j.ygyno.2015.08.026_bb0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm.1908","article-title":"A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer","volume":"15","author":"Farmer","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2015.08.026_bb0185","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T17:29:34Z","timestamp":1537378174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0090825815301177"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.08.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}